['type 2 diabetes mellitus']
['ttp273', 'placebo']

        Inclusion Criteria:

          -  The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and
             meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus.

          -  On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for
             the last 3 months prior to screening.

          -  Males. Females of non-childbearing potential.

          -  Generally stable health without a history of major surgery or significant injuries
             within the last year and without an active infection.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young,
             insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus,
             or history of diabetic ketoacidosis.

          -  Participation in a clinical trial and receipt of an investigational product within 30
             days.

          -  Participation in any formal weight loss program, or fluctuation of > 5% in body
             weight, or having received medications approved for weight loss within 3 months prior
             to screening or contemplating such therapy during the trial.

          -  Previous surgical treatment of obesity.

          -  Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice
             administered by someone other than the patient within 6 months prior to screening.

          -  Use of other diabetic agents except metformin within 3 months prior to Screening.

          -  History of pancreatitis.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening.

          -  History of hemolytic anemia, chronic transfusion requirement or other condition
             rendering HbA1c results unreliable.

          -  History of MEN-2 or family history of medullary thyroid cancer.

          -  History or presence of clinically significant disease (other than Type 2 diabetes
             mellitus).
      